Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

N/ACompletedNCT00819195

University of California, San Francisco17 enrolled

Overview

The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Multiple Sclerosis

Interventions

Glatiramer acetateDRUG

20 mg daily subcutaneous injection. Six-month duration.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Relapsing-remitting (RR) MS patients (McDonald criteria) * Ages 18-55 * Males and females * EDSS score ≤5 * No prior treatment with Copaxone * Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month Exclusion Criteria: * Treatment with Tysabri, Novantrone or cyclophosphamide * Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate) * Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis * Pregnancy

Locations (1)

UCSF Multiple Sclerosis Center

San Francisco, California, United States

Outcomes

Primary Outcomes

Production of inflammatory cytokines by monocytes and naive T cells.

Time frame: 0, 1, 2, 4, 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.